Vinpocetine In CerebralVascular Disease
Drug Develop Res 1988; 14: 199-204
Correlation Between Cerebral Circulation and Intellectual Impairments in Patients With "Aging Brain" and the Effect of Vinpocetine on Cerebral Circulation
Manabu Miyazaki Department of Internal Medicine, Bell-land Hospital, Sakai City, Osaka, Japan
The Doppler ultrasonic technique is useful for the examination of cerebral circulation as well as for the evaluation of cerebral circulation-improving drugs. This study deals with a correlation of cerebral circulation with intellectual impairment in subjects with aging brain syndrome and with measuring the effect of vinpocetine on cerebral circulation, using the Doppler technique. The correlation between cerebral circulation and intellectual impairment was first studied in 48 patients with aging brain and intellectual impairment. As a parameter for cerebral circulation, the Continuous lndex (CI), as calculated from the blood flow pattern recorded at the internal carotid artery, was used together with Hasegawa's Dementia Scale (HDS) for intellectual impairment. Second, blood flow change of the internal carotid and vertebral artery was measured after a single oral dose of 5 mg vinpocetine and after multiple oral doses of 5 mg vinpocetine three times daily for 7 days in six patients with aging brain. The mean correlation coefficient ® between CI and HDS was 0.391 (P < 0.01) in 48 patients. It was 0.612 (Fl < 0.01) in 27 patients with moderate to severe intellectual impairment, 0.735 (P < 0.01) in 14 patients with vascular type impairment, and 0.443 (not significant) in 10 patients with the Alzheimer type. The results suggest some correlation between cerebral circulation and intellectual impairment in the aging brain, especially in patients with the vascular type. An increase of blood flow was recognizable after a single oral dose of 5 mg vinpocetine.
J Am Geriatr Soc 1987 May;35(5):425-30
A double-blind placebo controlled evaluation of the safety & efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.
Balestreri R, Fontana L, Astengo F
In a double-blind clinical trial, vinpocetine, a synthetic ethyl ester of apovincamine, was shown to effect significant improvement in elderly patients with chronic cerebral dysfunction. Forty-two patients received 10 mg vinpocetine three times a day (tid) for 30 days, then 5 mg tid for 60 days. Matching placebo tablets were given to another 42 patients for the 90-day trial period. Patients on vinpocetine scored consistently better in all evaluations of the effectiveness of treatment including measurements on the Clinical Global Impression (CGI) scale, the Sandoz Clinical Assessment-Geriatric (SCAG) scale, and the Mini-Mental Status Questionnaire (MMSQ). There were no serious side effects related to the treatment drug.
Curr Therap Res 1986; 40: 702-2
A Double-Blind Clinical Trial of Vinpocetine in the Treatment of Cerebral Insufficiency of Vascular & Degenerative Origin.
E. MANCONI, P. BINAGHI, AND F. PITZUS. Department of Internal Medicine, University of Cagliari, Cagliari, Italy
We used vinpocetine, a synthetic ethyl ester of apovincamine, to treat 22 elderly patients with central nervous system degenerative disorders, in a double-blind clinical trial. Patients received 10-mg vinpocetine TID for 30 days, then 5 mg TID for 60 days. Another 18 elderly patients were given matching placebo tablets for the 90-day trial. Vinpocetine-treated patients scored consistently better in all evaluations of the effectiveness of treatment, including measurements on the Clinical Global Impressions (CGI) and Sandoz Clinical Assessment-Geriatric (SCAG) scales, and the Mini-Mental Status Questionnaire. According to CGI assessments, severity of illness decreased in 73% of the patients in the vinpocetine group at day 30 and 77% at day 90, and improvement was seen in 77% and 87% of the patients at days 30 and 90, respectively. Patients also showed statistically significant improvement for all SCAG items but one, at days 30 and 90. The physician rated the improvement in 59% of the vinpocetine-treated patients as "good" to "excellent". No serious side effects were related to the treatment drug.
Advances in therapy 1986; 4:201-4
A Double-Blind Placebo Controlled Evaluation of the Efficacy and Safety of Vinpocetine in the Treatment of Patients with Chronic Vascular or Degenerative Senile Cerebral Dysfunction
Marino Peruzza, M.D., Maurizio Dejacobis, M.D. Uníversity of Pavia.
G.B. Glustinian Regional Hospital. Venice, Italy
In a double-blind clinical trial, 22 elderly patients with cerebrovascular and central nervous system degenerative disorders were treated with vinpocetine, a synthetic ethyl ester of apovincamine. They received 10 mg vinpocetine t.i.d. for 30 days, then 5 mg t.i.d. for 60 days. Matching placebo tablets were given to another 20 elderly patients for the 90-day trial period. Patients on vinpocetine scored consistently better in all evaluations of the effectiveness of treatment including measurements on the Clinical Global Impressions and Sandoz Clinical Assessment-Geriatric Seales and the Mini-Mental Status Questionnaire. No serious side effects were related to the treatment drug.
Advances in therapy 1985; 2:53-6
Effect of Vinpocetine on Cerebral Blood Flow in Patients with Cerebrovascular Disorders
Norihiko Tamaki, M.D. Tadaki Kusunoki, M.D. Satoshi Matsumoto, M.D. Department of Neurosurgery. Kobe University School of Medicine. Kobe, Japan
The 133xenon inhalation method was used in an open-label clinical trial to examine changes in cerebral blood flow (CBF) after vinpocetine treatment in 13 patients with cerebrovascular disorders. In all patients, measurement of regional cerebral blood flow (RCBF) was made prior to and after treatment with vinpocetine 5 mg t.i.d. for five to seven weeks. In ten of the patients, treatment was continued for a total of 8 to 16 weeks with an additional RCBF measurement at the end of their treatment. The results showed a significant increase in the Initial Slope Index (ISI) values of mean total CBF, & RCBF for the involved hemisphere after six weeks of treatment with vinpocetine. The CBF for the involved lobe was significantly increased for ISI and flow rate of gray matter at six weeks and at the end of treatment. No adverse reactions were reported.
Arzneimittelforschung 1976;26(10a):1947-50
Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency.
Hadjiev D, Yancheva S
The effect of ethyl apovincaminate (RGH-4405, Cavinton) on the rheoencephalogram and memory functions was studied in 50 patients with ischaemic disturbances of cerebral circulation. The drug was administered in a single i.v. dose of 10 mg and orally three times daily 5 mg for a month. Improvement of cerebral circulation was observed after i.v. and oral medication. Blood flow was most markedly increased in the gray matter. The effect on arterial pressure was negligible. Improvement of memorizing capacity evaluated by psychological tests was recorded after one month of Cavinton treatment, associated with alleviation or complete disappearance of symptoms. No side-effects attributable to the drug were observed. It is pointed out that Cavinton is indicated in the treatment of ischaemic disorders of the cerebral circulation, particularly in chronic insufficiency.
Arzneimittelforschung 1976;26(10a):1945-7
Effect of ethyl apovincaminate on the cerebral circulation. Studies in patients with obliterative cerebral arterial disease.
Solti F, Iskum M, Czako E
The effect of ethyl apovincaminate (RGH-4405, Cavinton) on the cerebral and systemic circulations has been studied in detail in ten cases of cerebrovascular disease. 10 mg doses of Cavinton were given as infusion within 4-6 min; circulatory tests were carried out prior to administration of the drug and 3-6 min after. The principal results showed the following: On Cavinton cerebral vascular resistance was strongly reduced, while cerebral fraction of cardiac output significantly increased. On acute effect of the drug arterial mean pressure slightly decreased but cerebral blood flow nevertheless increased in general. Total vascular resistance also decreased but this decrease was less marked than that registered in cerebral vascular resistance.
Copyright © BrainMeta. All rights reserved.
Terms of Use | Last Modified Tue Jan 17 2006 12:39 am